ResMed CFO sells 1,000 company shares

RESMED INC Chief Financial Officer Brett Sandercock reported an open-market sale of 1,000 shares of ResMed Common Stock.

Filing Impact

(Neutral)

Filing Sentiment

(Negative)How Sentiment works

Sentiment and the balance of points

Rhea-AI Sentiment reads the wording of the document, how positive or negative its language is on a 1 to 5 scale. The balance of points shown with the takes weighs what the document actually discloses, so the two can disagree, for example when a trial that missed its main goal is described in upbeat language.

How Sentiment works How the balance works

Form Type

Rhea-AI Filing Summary

RESMED INC Chief Financial Officer Brett Sandercock reported an open-market sale of 1,000 shares of ResMed Common Stock. The shares were sold at a price of $224.31 per share.

After this transaction, he holds 83,495 shares directly. The sale was conducted under a Rule 10b5-1 plan adopted on February 19, 2025.

Insider Trade Summary 10b5-1

Net Seller: 1,000 shares

Net Sell 1 txn

Insider Sandercock Brett

Role Chief Financial Officer

Sold 1,000 shs ($224K)

Type	Security	Shares	Price	Value
Sale	ResMed Common Stock	1,000	$224.31	$224K

Holdings After Transaction: ResMed Common Stock — 83,495 shares (Direct)

Footnotes (1)

F1. The transaction was conducted under a Rule 10b5-1 plan adopted February 19, 2025.

Key Figures

Shares sold: 1,000 shares Sale price per share: $224.31 per share Shares held after transaction: 83,495 shares

3 metrics

Shares sold 1,000 shares ResMed Common Stock, open-market sale

Sale price per share $224.31 per share ResMed Common Stock sale on 2026-04-01

Shares held after transaction 83,495 shares Direct ownership following sale

Key Terms

Rule 10b5-1 plan, open-market sale, ResMed Common Stock

3 terms

Rule 10b5-1 plan regulatory

"The transaction was conducted under a Rule 10b5-1 plan adopted February 19, 2025."

A Rule 10b5-1 plan is a prearranged, written schedule that lets corporate insiders buy or sell company stock at set times or amounts, even if they later learn material nonpublic information. Think of it like setting an automatic thermostat for trades: it creates a clear record that trades were planned in advance, reducing the risk of insider-trading accusations and helping investors trust that insider transactions are routine rather than based on secret information.

open-market sale financial

"transaction_action: open-market sale of ResMed Common Stock"

An open-market sale is when a shareholder sells existing shares directly on a public exchange to any willing buyer, rather than through a private deal. Think of it like putting goods on a busy market stall where price is set by supply and demand; for investors it matters because such sales increase available supply, can put short-term downward pressure on the stock price, and signal changes in liquidity or investor confidence.

ResMed Common Stock financial

"security_title: ResMed Common Stock reported as non-derivative"

FAQ

AI-generated questions and answers. How Rhea-AI works. Not financial advice.

What insider transaction did RESMED INC (RMD) disclose for Brett Sandercock?

RESMED INC disclosed that Chief Financial Officer Brett Sandercock completed an open-market sale of 1,000 shares of ResMed Common Stock. This Form 4 filing reports the details of that transaction, including price, date, and his direct holdings after the sale.

How many RESMED INC (RMD) shares did the CFO sell and at what price?

The Chief Financial Officer sold 1,000 shares of ResMed Common Stock at a price of $224.31 per share. The transaction is classified as an open-market sale of non-derivative securities and is reported as a sell transaction on the Form 4.

How many RESMED INC (RMD) shares does Brett Sandercock hold after this Form 4 sale?

Following the reported transaction, Brett Sandercock holds 83,495 shares of ResMed Common Stock directly. This post-transaction ownership figure is disclosed in the Form 4 and reflects his direct holdings after the 1,000-share open-market sale.

What does the Form 4 say about a Rule 10b5-1 plan for RESMED INC (RMD) CFO?

The Form 4 states that the transaction was conducted under a Rule 10b5-1 plan adopted on February 19, 2025. This indicates the sale followed a pre-established trading plan referenced in the filing’s footnote for Brett Sandercock.

Was the RESMED INC (RMD) CFO’s transaction in derivative or common stock?

The reported transaction involved ResMed Common Stock as a non-derivative security. The Form 4 classifies the 1,000-share sale as a non-derivative open-market transaction and shows no accompanying derivative security exercises or conversions in this filing.

AI-generated analysis. How Rhea-AI works. Not financial advice.

Form 4 Insider Transactions: What Each Field Means →

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google

Accepted by SEC EDGAR 04/03/2026 - 07:29 AM EDT

SEC Form 4

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0287
Estimated average burden
hours per response:			0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.

1. Name and Address of Reporting Person^*

Sandercock Brett

(Last)

(First)

(Middle)

RESMED INC.

9001 SPECTRUM CENTER BLVD.

(Street)

SAN DIEGO

CALIFORNIA

92123

(City)

(State)

(Zip)

UNITED STATES

(Country)

2. Issuer Name and Ticker or Trading Symbol
RESMED INC [ RMD ]

5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

	Director	10% Owner
X	Officer (give title below)	Other (specify below)
	Chief Financial Officer

2a. Foreign Trading Symbol

3. Date of Earliest Transaction (Month/Day/Year)
04/01/2026

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

4. If Amendment, Date of Original Filed (Month/Day/Year)

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	Code	V	Amount	(A) or (D)	Price		6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
ResMed Common Stock	04/01/2026		S⁽¹⁾		1,000	D	$224.31	83,495	D

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares	8. Price of Derivative Security (Instr. 5)		10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)

Explanation of Responses:

1. The transaction was conducted under a Rule 10b5-1 plan adopted February 19, 2025.

	/s/ Brett Sandercock, Chief Financial Officer	04/02/2026
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.
* Form 4: SEC 1474 (03-26)

Source: View Original Filing on SEC EDGAR